
Lateral Capital

Amgen’s clinical trial program investigates a potential first-in-class mechanism of action for moderate to severe atopic dermatitis
SCIENCE & INNOVATION 01 18 2023
Often referred to as the founder of BiTE® technology, the Amgen Research Munich scientist received the George B Rathmann Award for Scientific Excellence at a recent leadership meeting
2 images — click to enlarge
No questions yet. Be the first to ask about Amgen.
Similar listings buyers compare against this one.

Lateral Capital

Dorado Capital Partners

Social Tech Trust

Mehta Ventures

Nobska Ventures

BCBS Venture Partners
Everything here links back to the same verified catalogue. Pick your next stop.